Aspirin has selective benefit in colorectal cancer | Science News

Be a Champion for Science

Get your subscription to

Science News when you join.


Aspirin has selective benefit in colorectal cancer

Patients with gene mutation appear to gain advantage from drug

5:51pm, October 24, 2012

The mystery of why aspirin helps some colorectal cancer patients but not others may be partially solved. A new study finds that the drug seems to extend survival in patients whose tumors harbor a specific genetic mutation, while patients lacking the mutation get no survival advantage from regularly taking the pills.

The study, in the Oct. 25 New England Journal of Medicine, may lead to standardized testing of colorectal cancer patients for the mutation, in a gene called PIK3CA, to see who would benefit from aspirin use.

“We may be witnessing a game changer,” says Boris Pasche, an oncologist at the University of Alabama at Birmingham who wasn’t part of the study team. “I wouldn’t be surprised to see labs beginning to test for this mutation quickly.”

This article is available only to subscribing members. Join the Society today or Log in.

Get Science News headlines by e-mail.

More from Science News